1. Home
  2. ELME vs DNTH Comparison

ELME vs DNTH Comparison

Compare ELME & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elme Communities

ELME

Elme Communities

HOLD

Current Price

$17.30

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$43.15

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELME
DNTH
Founded
1960
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ELME
DNTH
Price
$17.30
$43.15
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$15.00
$68.00
AVG Volume (30 Days)
1.5M
746.7K
Earning Date
10-23-2025
11-05-2025
Dividend Yield
4.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$246,959,000.00
$3,078,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.10
N/A
52 Week Low
$13.95
$13.37
52 Week High
$18.08
$44.95

Technical Indicators

Market Signals
Indicator
ELME
DNTH
Relative Strength Index (RSI) 68.52 65.87
Support Level $16.38 $39.82
Resistance Level $17.40 $44.95
Average True Range (ATR) 0.18 2.44
MACD 0.07 0.41
Stochastic Oscillator 92.65 83.11

Price Performance

Historical Comparison
ELME
DNTH

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: